Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
taxane + carboplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Taxane + carboplatin is a combination chemotherapy regimen consisting of a taxane (most commonly paclitaxel or docetaxel) and carboplatin. This combination is widely used to treat various solid tumors, including ovarian, lung, breast (notably triple-negative and HER2-positive), endometrial (womb), and cervical cancers. Taxanes work by stabilizing microtubules in cancer cells, thereby inhibiting cell division and promoting apoptosis. Carboplatin is a platinum-based agent that causes DNA crosslinking and prevents DNA replication in rapidly dividing cells. The two drugs are typically administered intravenously in cycles every 3–4 weeks. The combination has demonstrated improved efficacy over single-agent therapy or older regimens such as cisplatin-based combinations for certain cancers[1][3][5][6].
- Other names
- PCCarboTaxolTP regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on taxane + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on taxane + carboplatin.